Two medicines, side by side
Alfuzosin vs azelastine
Alfuzosin is labeled for enlarged prostate (bph); azelastine for allergies. Their labels share no use, so they are not alternatives to each other. Drugs@FDA records approvals of alfuzosin since 2003 and of azelastine since 1996. Pharmacies paid $0.105 per alfuzosin HCl ER 10 mg tablet and $0.273 per mL (Azelastine 0.1% (137 mcg) spry) (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, alfuzosin is an alpha-adrenergic blocker and azelastine a histamine-1 receptor antagonist.
Check it at the source: the alfuzosin FDA label on DailyMed (effective December 5, 2024); the azelastine FDA label on DailyMed (effective December 4, 2025).
Highlights of the alfuzosin record
Alfuzosin (Uroxatral) · label of December 5, 2024
Used for
From the label: indicationsUROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is an alpha adrenergic antagonist, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. ( 1 ) Important Limitations of Use: UROXATRAL is not indicated for treatment of hypertension. ( 1.1 ) UROXATRAL is not indicated for use in the pediatric population. […]
On the market
- Earliest approval on file
- June 12, 2003
- Generic labelers
- 10 labelers
- Pharmacy cost
- $0.105 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Highlights of the azelastine record
Azelastine (Astepro) · label of December 4, 2025
Used for
From the label: indicationsUses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: nasal congestion runny nose sneezing itchy nose
On the market
- Earliest approval on file
- November 1, 1996
- Generic labelers
- 22 labelers
- Pharmacy cost
- $0.273 per mL
Supply and safety
- Shortage
- No current entry
- Recalls
- 3
Source: FDA drug labels via openFDA (Alfuzosin label of December 5, 2024, Azelastine label of December 4, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do alfuzosin and azelastine differ on the record?
In FDA's classes, alfuzosin is an alpha-adrenergic blocker and azelastine a histamine-1 receptor antagonist.
Generics: alfuzosin since 2011; azelastine since 2009 (Drugs@FDA).
| Alfuzosin | Azelastine | |
|---|---|---|
| Labeled for | Enlarged prostate (BPH) | Allergies |
| Pharmacologic class | alpha-Adrenergic Blocker | Histamine-1 Receptor Antagonist |
| How it works (label) | Alfuzosin is a selective antagonist of post-synaptic alpha 1 -adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra. | n/a |
| Half-life (label) | Following oral administration of UROXATRAL 10 mg tablets, the apparent elimination half-life is 10 hours. | n/a |
| Earliest approval on file (Drugs@FDA) | June 12, 2003 | November 1, 1996 |
| First generic approved | July 18, 2011 | April 30, 2009 |
| Generic labelers (NDC) | 10 labelers | 22 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.105 per tablet (Alfuzosin HCl ER 10 mg tablet) | $0.273 per mL (Azelastine 0.1% (137 mcg) spry) |
| 12-month price change | -0.1% | -4% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 1 | 3 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 5,746 | 18,108 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to alfuzosin
- every medicine labeled for the same conditions